Rebekah Guy
Pain Medicine · Boise, IDNPI 1154542355
Payments from drug & device makers
What this record shows
26 manufacturers reported payments, led by Neuronetics, Inc. at 44.5% of the total. Reporting peaked in 2021 at $1,613 and has fallen 91.0% since, to $145 in 2025. That places this record below the midpoint for pain medicine clinicians in ID, where the typical reported total is $4,838.
Across 63 payments — averaging $41.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$1K
- Biodelivery Sciences International, Inc.$188
- Merz North America, Inc.$182
- Galderma Laboratories, L.p.$151
- Idorsia Pharmaceuticals US Inc$145
- Amgen$126
- plus $665 from 20 others
What the payments were for
- Travel & lodging$1,16845%
- Food & beverage$1,45655%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 1 | $1,168 |
| Biodelivery Sciences International, Inc. | 18 | $188 |
| Merz North America, Inc. | 4 | $182 |
| Galderma Laboratories, L.p. | 3 | $151 |
| Idorsia Pharmaceuticals US Inc | 3 | $145 |
| Amgen(2 entities) | 6 | $126 |
| Vertex | 1 | $122 |
| Daiichi Sankyo Inc. | 1 | $113 |
| Pfizer | 3 | $53 |
| AbbVie | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $38 |
| Painteq LLC | 2 | $37 |
| Eisai Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Abbott | 1 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Fidia Pharma USA Inc. | 2 | $21 |
| Boston Scientific | 1 | $18 |
| Merck | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| AstraZeneca | 1 | $13 |
| MDD US Operations, LLC | 1 | $13 |
| Si-bone, Inc. | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
| Stimwave Technologies Incorporated | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY$1,168
- QUVIVIQ$125
- JOURNAVX$122
- Morphabond ER$113
How this compares
$2,624 in reported general payments places this provider in the 40th percentile of 32 pain medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 161 | $122,889 |
| UbrelvyUbrogepant | 22 | $36,351 |
| Fentanyl | 135 | $31,485 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 808 | $31,135 |
| Xtampza ErOxycodone Myristate | 33 | $31,102 |
| Nucynta ErTapentadol Hcl | 24 | $28,680 |
| Morphine Sulfate ErMorphine Sulfate | 603 | $20,661 |
| Oxycodone Hcl | 596 | $20,538 |
| NucyntaTapentadol Hcl | 22 | $20,270 |
| Buprenorphine | 66 | $18,010 |
| MovantikNaloxegol Oxalate | 44 | $17,445 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 303 | $11,595 |
| BelbucaBuprenorphine Hcl | 14 | $10,917 |
| Pregabalin | 159 | $5,035 |
| SymproicNaldemedine Tosylate | 11 | $4,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Nucynta, Belbuca | $23 | $90,96993 claims |
| AbbVieUbrelvy | $46 | $36,35122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 32 pain medicine providers in Idaho.
Other pain medicine in Boise
- Jason WilliamsBoise$177K
- Sandra ThompsonBoise$58K
- Christopher VaughanBoise$26K
- William BinegarBoise$5K
- Daniel MarshBoise$2K
- Clinton MallariBoise$1K
- Slavik OsipchukBoise$146
- Richard DuboseBoise$20
- Jessica JamesonPost Falls$261K
- Daniel SmithIdaho Falls$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.